Chevron makes another investment, Houston researchers nationally recognized, and more innovation news

Short Stories

From Houston inventors being recognized to Chevron's latest investment, here's what innovation news you need to know. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston's innovation news hasn't quite slowed yet for the holidays. This most recent news roundup includes lots of money raised, a new contract for a Houston startup, innovators recognized and more.

For more daily innovation news, subscribe to InnovationMap's newsletter, which goes out every weekday at 7 am.

Chevron Technology Ventures invests in Texas company

Courtesy of CTV

Houston-based Chevron Technology Ventures has contributed to Austin-based motor tech company Infinitum Electric's $12.5 million Series B round of financing. New Mexico-based Cottonwood Technology Fund and includes participation AJAX Strategies and other individual investors.

The company plans to use the funds to build out its research and development, engineering, supply chain, and production teams.

"Infinitum's mission aligns well with our goals for the Future Energy Fund," says Barbara Burger, president of CTV, in a release. "The purpose of the Future Energy Fund is to invest in breakthrough energy technologies that reflect Chevron's commitment to lower emission energy sources and that are integral to low-carbon and efficient value chains."

4 Houston researchers named fellows of the National Academy of Inventors

ideas

Getty Images

The National Academy of Inventors named 168 academic innovators to NAI Fellow status — and four conduct their research right here in Houston. The program "highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society," reads the news release.

The four Houston inventors and their institutions are as follows:

List ranks Houston's fastest growing companies

Chart via Grojo.com

Growjo named the 100 fastest-growing companies in Houston for 2019, and, while the study notes the city's large oil and gas and medical industries, also acknowledges its growing tech and software scene. The companies were selected by a myriad of factors.

"Our algorithm is based on multiple datasets including employee growth, estimated revenue growth, valuations, quality and quantity of funding, hiring announcements, current job openings, leadership team announcements, and numerous other growth triggers," reads the website.

The top five companies on the list are:

  1. Midcoast Energy, which has 183 employees and a 17 percent employee growth rate.
  2. ibüümerang, which has 528 employees, and a 633 percent employee growth rate.
  3. Arion, which has 136 employees and a 216 percent employee growth rate.
  4. GoExpedi, which as 59 employees and a 119 percent employee growth rate.
  5. Code Ninjas, which has 338 employees and a 63 percent employee growth rate.

For the full list, visit Growjo.com.

TMCx company wins awards 

Image via abilitechmedical.com

Abilitech Medical, which recently completed the TMCx program, has taken home some wins in Minnesota, where it's based. The company was named named among the state's topmed tech companies by the Minnesota High Tech Association at the 2019 TEKNE awards and 2019, as well as the grand prize winner and top woman-led business by the University of Minnesota's business school at its 2019 Minnesota Cup competition.

The medical device company's technology includes the Abilitech™ Assist, which assists patients with Multiple Sclerosis, rehabilitating from stoke, or other conditions with eating, drinking, and using a computer.

"We've met so many people whose lives will be changed with this innovation," says CEO and founder Angie Conley in a news release. "Through the Texas Medical Center accelerator, we met Dr. Hany Samir who championed our upcoming stroke study."

Samir is a cardiac anesthesiologist at Houston Methodist. He lost his ability to work and perform simple daily functions after a stroke debilitated his left arm.

"I'm unable to practice the medicine I love. I want to hold my wife again with two hands and enjoy dinner with her, without having her cut my food. I want to have a cup of coffee without asking for help," says Samir in the release. "Regaining function in my arm will restore my life."

Pandata Tech receives Department of Defense contract

Photo courtesy of Pandata Tech

Houston-based ​Pandata Tech secured a contract with the United States Department of Defense from the Rapid Sustainment Office of the the United States Air Force last month. The Phase II contract will allow the company to work with Joint Base Elmendorf-Richardson in Alaska to develop a scalable data quality platform.

The access to data will aid in natural disasters, per the release. The goal of the contract would be for a Phase III contract and an opportunity to scale the technology into other branches of military. The company also had a Phase I contract signed in August before securing the Phase II in November.

"Pandata Tech's proprietary DQM software was built during a development partnership with one of the world's largest offshore drilling companies. Because the technology was tested and built with offshore drilling data, the shift to aircraft carriers would be smooth," explains Gustavo Sanchez, co-founder of Pandata Tech, in a news release.

Houston company receives Department of Energy funding

Photo via aerominepower.com

The U.S. Department of Energy's National Renewable Energy Laboratory — with funding from the DOE's Office of Energy Efficiency and Renewable Energy Wind Energy Technologies Office — selected a Houston company for its Competitiveness Improvement Project.

Westergaard Solutions, founded by Houstonian Carsten Westergaard, was named among the 2019 CIP Awardees. Among the company's assets is AeroMine, which competed in the most recent Houston cohort in MassChallenge Texas. The company "will implement an innovative building-integrated wind generation concept with no external moving parts, moving from a preliminary conceptual design to a pre-production prototype design that is ready for testing," according to the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston health tech innovator collaborates on promising medical device funded by DOD

team work

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect.

The team working on this new research seeks to minimize near-eventualities like blood clot formation, blood damage, and driveline complications such as infection and limitations in mobility. The four institutions will try to innovate with a device featuring new engineering designs, antithrombotic slippery hydrophilic coatings (SLIC), wireless power transfer systems, and magnetically levitated driving systems.

Wang and her team believe that the non-contact-bearing technology will help to decrease the risk of blood clotting and damage when implanting an LVAD. The IDEA Lab will test the efficacy and safety of the SLIC LVAD developed by the multi-institutional team with a lab-bench-based blood flow loop, but also in preclinical models.

“The Texas Heart Institute continues to be a leading center for innovation in mechanical circulatory support systems,” said Joseph G. Rogers, MD, the president and CEO of THI, in a press release.

“This award will further the development and testing of the SLIC LVAD, a device intended to provide an option for a vulnerable patient population and another tool in the armamentarium of the heart failure teams worldwide.”

If it works as hypothesized, the SLIC LVAD will improve upon current LVAD technology, which will boost quality of life for countless heart patients. But the innovation won’t stop there. Technologies that IDEA Lab is testing include wireless power transfer for medical devices and coatings to reduce blood clotting could find applications in many other technologies that could help patients live longer, healthier lives.

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."



An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

View All Listings